International Law Regulation of Access to Health Technologies
- Авторлар: Malichenko V.1
-
Мекемелер:
- Institute of Legislation and Comparative Law under the Government of Russian Federation
- Шығарылым: Том 14, № 5 (2021)
- Беттер: 256-285
- Бөлім: Law in the Modern World
- URL: https://journals.rcsi.science/2072-8166/article/view/318145
- DOI: https://doi.org/10.17323/2072-8166.2021.5.256.285
- ID: 318145
Дәйексөз келтіру
Толық мәтін
Аннотация
Негізгі сөздер
Авторлар туралы
Vladislav Malichenko
Institute of Legislation and Comparative Law under the Government of Russian Federation
Email: noreply@hse.ru
ORCID iD: 0000-0003-3136-8054
Candidate of Science (Law), Senior Researcher
Әдебиет тізімі
- Bermudez J., Hoen E. (2010) The UNITAID patent pool initiative: bringing patents together for the common good. The open AIDS Journal, vol. 4, pp. 37-40.
- Chien C. (2003) Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation? Berkeley Technology Law Journal, vol. 18, pp. 853-907.
- DiMasi J.A., Grabowski H.G. (2007) The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics, vol. 28, issue 4-5, pp. 469-479.
- DiMasi J.A., Hansen R.W., Grabowski H.G. (2003) The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, vol. 22, issue 2, pp. 151-185.
- Dill S., Ahn J. (2014) Drug shortages in developed countries-reasons, therapeutic consequences, and handling. European Journal of Clinic Pharmacology, vol. 70, no. 12, pp. 1405-1412.
- Dosi G., Marengo L., Staccioli J., Virgillito M. (2021) Big pharma and monopoly capitalism: a long-term view. Pisa: Sant'Anna School of Advanced Studies, pp. 1-36.
- Dutfield G. (2003) Intellectual property rights and the life science industries: a twentieth century history. London: Routledge, 304 p.
- Mukherjee S. (2017) Emerging infectious diseases: Epidemiological perspective. Indian Journal of Dermatology, vol. 5, pp. 459-467.
- Plomer A. (2021) IP Rights and Human Rights. What History Tells Us and Why It Matters. The Right to Science. Cambridge: University Press, pp. 54-76.
- Ruikai D., Luanjiao H. (2021) Inclusive communications in COVID-19: a virtual ethnographic study of disability support network in China. Disability & Society, pp. 1-19.
- Schlander M., Hernandez-Villafuerte K., Cheng C. (2021) How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmaco Economics, vol. 39, pp. 1243-1269.
- Schweitzer S.O., Lu Z.J. (2018) Pharmaceutical economics and policy: perspectives, promises, and problems. Oxford: Oxford University Press, 432 p.
- Solovy E., Krishnamurthy P. (2017) TRIPS Agreement Flexibilities and Their Limitations: A Response to the UN Secretary-Generals' s High Level Panel Report on Access to Medicines. Geo. Wash. Int'l L. Review, vol. 50, pp. 1-19.
- Tucker E.L. et al. (2020) The Drug Shortage Era: A Scoping Review of the Literature 2001-2019. Clinic Pharmacology Therapy, vol. 108, pp. 1150-1155.
- White C. (2021) Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States. Journal of the American Pharmacists Association, vol. 1, pp. 93-98.
- Wirtz V.J., Hogerzeil H.V. et al. (2017) Essential medicines for universal health coverage. The Lancet, vol. 389, pp. 403-476.
- Yegros-Yegros A., Van de Klippe W., Abad-Garcia M.F., Rafols I. (2020) Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives. Health research policy and systems, no. 18, pp. 1-14.
Қосымша файлдар
